Patients with a bleeding disorder called immune thrombocytopenia (ITP) are at risk for blood loss if they need to have surgery. Because their blood doesn’t clot as it should, ITP patients are commonly treated before surgery with intravenous immune globulin (IVIg), which helps their blood clot by increasing the number of platelets. But a study published in The Lancet Haematology and led by Dr. Donald Arnold, director of the McMaster Centre for Transfusion Research, shows that an oral medication that stimulates the production of platelets, called eltrombopag, is an effective alternative to IVIg for this patient group.
Why is this important? As discussed in a previous R.E.D. blog post, demand for IVIg in Canada and around the world is high and keeps growing— but the supply of this blood-derived drug is limited. According to Dr. Arnold, accessibility to alternative treatments such as eltrombopag could play an important role in improving IVIg availability overall. “A global shortage of immune globulin products is anticipated,” he says. “And this shortage could possibly be compounded by the COVID-19 pandemic.”
To learn more about the study, read our latest Research Unit.
What’s next for Dr. Arnold and his team? Dr. Arnold explains that in Canada, IVIg is provided to hospitals by Canadian Blood Services, but it is an expensive treatment option. “The next step for us is to better understand the financial costs and benefits of eltrombopag as an alternative treatment.”
MCTR receives funding support from Canadian Blood Services through the Transfusion Medicine Research Program Support Award.
Canadian Blood Services – Driving world-class innovation
Through discovery, development and applied research, Canadian Blood Services drives world-class innovation in blood transfusion, cellular therapy and transplantation—bringing clarity and insight to an increasingly complex healthcare future. Our dedicated research team and extended network of partners engage in exploratory and applied research to create new knowledge, inform and enhance best practices, contribute to the development of new services and technologies, and build capacity through training and collaboration. Find out more about our research impact.
The opinions reflected in this post are those of the author and do not necessarily reflect the opinions of Canadian Blood Services nor do they reflect the views of Health Canada or any other funding agency.
Related blog posts
Blood plasma-derived IVIg holds promise as a treatment for Alzheimer’s disease. A new study suggests that combining IVIg with a new drug delivery technique that helps get IVIg into the brain could increase its effectiveness and help make the best use of this precious treatment.
Wonder drug it may be, but IVIg is a slippery fish. Even after 60 years, little is known about precisely how it works. An encounter with a scientist The first thing you notice when you walk into Dr. Don Branch’s office at 67 College Street in Toronto is how small it seems. And colourful, owing to an...
When a person is in dire need of blood, a blood transfusion seems like a simple solution. A donor donates blood, and eventually a patient in need receives it. Yet, in reality this life-saving medical procedure, as safe as it may be, is not that simple.